Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. [PDF]
Pharmacol Res Perspect, 2018 Hole K +5 more
europepmc +1 more source
Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity? [PDF]
Br J Clin Pharmacol, 2018 Neuhoff S, Tucker GT.
europepmc +1 more source
Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment. [PDF]
Clin Pharmacol, 2019 Li Y +5 more
europepmc +1 more source
Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker. [PDF]
Br J Clin Pharmacol, 2018 Kuypers DRJ, Vanhove T.
europepmc +1 more source
Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker. [PDF]
Br J Clin Pharmacol, 2018 Gjestad C +3 more
europepmc +1 more source
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. [PDF]
Br J Clin Pharmacol, 2017 Gjestad C +3 more
europepmc +1 more source
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 Størset E +5 more
europepmc +1 more source
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. [PDF]
Br J Clin Pharmacol, 2016 Vanhove T +5 more
europepmc +1 more source
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 Vanhove T +4 more
europepmc +1 more source
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. [PDF]
Br J Clin Pharmacol, 2015 de Graan AJ +8 more
europepmc +1 more source